Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Lymphoma 2Small Cell Lung Carcinoma 1Sarcoma 1Prostatic Neoplasms 1Neoplasms 1Neoplasm, Residual 1Lymphoproliferative Disorders 1Lymphomatoid Granulomatosis 1Lymphoma, Non-Hodgkin 1Lung Neoplasms 1Leukemia, Hairy Cell 1Leukemia 1Epstein-Barr Virus Infections 1Carcinoma, Transitional Cell 1

Interventions

Rituximab 8Vemurafenib 4Cyclophosphamide 4Cladribine 4Specimen Handling 3Diphenhydramine 3Biopsy 3Acetaminophen 3obinutuzumab 2ibrutinib 2fludarabine phosphate 2fludarabine 2binimetinib 2Dexamethasone 2Calcium Dobesilate 2CT-P10 2Bendamustine Hydrochloride 2venetoclax 1tovorafenib 1polatuzumab vedotin 1pembrolizumab 1immunotoxin HA22 1encorafenib 1dexamethasone acetate 1dexamethasone 21-phosphate 1brexucabtagene autoleucel 1auricularum 1acalabrutinib 1Whole-Body Irradiation 1Valganciclovir 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Leukemia, Hairy Cell × Caves × 1 year × Clear all
NCT00923013 2025-08-08

Cladribine With Simultaneous or Delayed Rituximab to Treat Hairy Cell Leukemia

National Institutes of Health Clinical Center (CC)

Phase 2 Active not recruiting
175 enrolled 16 charts
Other hematologic neoplasm

Leukemia, Leukemia, Hairy Cell, Neoplasm, Residual

Data powered by HemOnc (CC BY 4.0) Colophon âš¡